v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues:    
Revenue from collaborative arrangement $ 0 $ 65,343
Operating expenses:    
Research and development 14,070,107 16,090,902
General and administrative 7,879,886 9,024,970
Total operating expenses 21,949,993 25,115,872
Loss from operations (21,949,993) (25,050,529)
Other income (expense):    
Interest income 439,593 808,077
Change in fair value of common stock warrant liabilities 4,137,703 3,712,872
(Loss) gain on investment in affiliated entity (2,103,688) 695,131
Net unrealized gain on available-for-sale equity securities 79,077 140,234
Other expense, net (285,490) (482)
Net loss $ (19,682,798) $ (19,694,697)
Net loss per share    
Basic (in dollars per share) $ (0.28) $ (0.51)
Diluted (in dollars per share) $ (0.28) $ (0.51)
Weighted average number of common shares used to compute net loss per share    
Basic (in shares) 69,101,910 38,613,653
Diluted (in shares) 69,101,910 38,613,653